(VIANEWS) – Merck (MRK), Boston Properties (BXP), TeklaLife Sciences Investors (HQL) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio as yet. The payout ratio in itself isn’t a promise of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. Merck (MRK)
2114.29% Payout Ratio
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Earnings Per Share
As for profitability, Merck has a trailing twelve months EPS of $0.14.
PE Ratio
Merck has a trailing twelve months price to earnings ratio of 886.5. Meaning, the purchaser of the share is investing $886.5 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.9%.
Yearly Top and Bottom Value
Merck’s stock is valued at $124.11 at 07:23 EST, under its 52-week high of $130.24 and way above its 52-week low of $99.14.
Sales Growth
Merck’s sales growth is 9.8% for the current quarter and 5.3% for the next.
2. Boston Properties (BXP)
323.97% Payout Ratio
Boston Properties, Inc. (NYSE: BXP) (“BXP” or the “Company”) is the largest publicly traded developer, owner, and manager of premier workplaces in the United States, concentrated in six dynamic gateway markets – Boston, Los Angeles, New York, San Francisco, Seattle, and Washington, DC. BXP has delivered places that power progress for our clients and communities for more than 50 years. BXP is a fully integrated real estate company, organized as a real estate investment trust (REIT). Including properties owned by joint ventures, BXP's portfolio totals 53.3 million square feet and 188 properties, including 10 properties under construction/redevelopment. BXP's properties include 167 office properties, 14 retail properties (including two retail properties under construction/redevelopment), six residential properties (including one residential property under construction) and one hotel. BXP is well-known for its inhouse building management expertise and responsiveness to clients' needs. BXP holds a superior track record of developing premium Central Business District (CBD) office buildings, successful mixed-use complexes, suburban office centers and build-to-suit projects for a diverse array of creditworthy clients. BXP actively works to promote its growth and operations in a sustainable and responsible manner. BXP has earned a twelfth consecutive GRESB “Green Star” recognition and the highest GRESB 5-star Rating. BXP, an S&P 500 company, was founded in 1970 by Mortimer B. Zuckerman and Edward H. Linde and became a public company in 1997.
Earnings Per Share
As for profitability, Boston Properties has a trailing twelve months EPS of $1.21.
PE Ratio
Boston Properties has a trailing twelve months price to earnings ratio of 54.38. Meaning, the purchaser of the share is investing $54.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.52%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 4% and a negative 18.2%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Boston Properties’s EBITDA is 7.79.
Yearly Top and Bottom Value
Boston Properties’s stock is valued at $65.80 at 07:23 EST, way below its 52-week high of $73.97 and way higher than its 52-week low of $46.18.
3. TeklaLife Sciences Investors (HQL)
162.03% Payout Ratio
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Earnings Per Share
As for profitability, TeklaLife Sciences Investors has a trailing twelve months EPS of $0.79.
PE Ratio
TeklaLife Sciences Investors has a trailing twelve months price to earnings ratio of 17.46. Meaning, the purchaser of the share is investing $17.46 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.28%.
Yearly Top and Bottom Value
TeklaLife Sciences Investors’s stock is valued at $13.79 at 07:23 EST, below its 52-week high of $14.37 and way above its 52-week low of $11.34.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Feb 21, 2024, the estimated forward annual dividend rate is 1.33 and the estimated forward annual dividend yield is 9.57%.
4. BlackRock New York Municipal Income Trust (BNY)
65.43% Payout Ratio
BlackRock New York Municipal Income Trust is a closed ended fixed income mutual fund launched by BlackRock, Inc. It is managed by BlackRock Advisors, LLC. The fund invests in fixed income markets. It invests primarily in the investment grade municipal bonds exempt from federal income taxes and New York State and New York City personal income taxes. BlackRock New York Municipal Income Trust was formed on July 26, 2001 and is domiciled in United States.
Earnings Per Share
As for profitability, BlackRock New York Municipal Income Trust has a trailing twelve months EPS of $-0.03.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -0.49%.
Yearly Top and Bottom Value
BlackRock New York Municipal Income Trust’s stock is valued at $10.64 at 07:23 EST, below its 52-week high of $10.80 and way higher than its 52-week low of $8.60.
Revenue Growth
Year-on-year quarterly revenue growth declined by 1.7%, now sitting on 19.59M for the twelve trailing months.
Moving Average
BlackRock New York Municipal Income Trust’s worth is above its 50-day moving average of $10.50 and above its 200-day moving average of $9.95.
5. IDACORP (IDA)
62.26% Payout Ratio
IDACORP, Inc., together with its subsidiaries, engages in the generation, transmission, distribution, purchase, and sale of electric energy in the United States. The company operates 17 hydropower generating plants located in southern Idaho and eastern Oregon; three natural gas-fired plants in southern Idaho; and interests in two coal-fired steam electric generating plants located in Wyoming and Nevada. As of December 31, 2021, it had approximately 4,843 pole-miles of high-voltage transmission lines; 23 step-up transmission substations located at power plants; 21 transmission substations; 10 switching stations; 30 mixed-use transmission and distribution substations; 187 energized distribution substations; and 28,570 pole-miles of distribution lines, as well as provides electric utility services to approximately 604,000 retail customers in southern Idaho and eastern Oregon. The company serves commercial and industrial customers, which involved in food processing, electronics and general manufacturing, agriculture, health care, government, and education. It also invests in housing and other real estate tax credit investments. IDACORP, Inc. was founded in 1915 and is headquartered in Boise, Idaho.
Earnings Per Share
As for profitability, IDACORP has a trailing twelve months EPS of $5.14.
PE Ratio
IDACORP has a trailing twelve months price to earnings ratio of 17.18. Meaning, the purchaser of the share is investing $17.18 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.14%.
6. BlackRock Resources (BCX)
48.25% Payout Ratio
Blackrock Resources & Commodities Strategy Trust is a closed-ended equity mutual fund launched by BlackRock, Inc. It is co-managed by BlackRock Advisors, LLC and BlackRock International Limited. The fund invests in the public equity markets of the United States. It seeks to invest in stocks of companies operating in the commodities or natural resources sectors. The fund also invests through derivatives with exposure to commodity or natural resources companies, with an emphasis on option writing. Blackrock Resources & Commodities Strategy Trust was formed on March 30, 2011 and is domiciled in the United States.
Earnings Per Share
As for profitability, BlackRock Resources has a trailing twelve months EPS of $1.26.
PE Ratio
BlackRock Resources has a trailing twelve months price to earnings ratio of 6.59. Meaning, the purchaser of the share is investing $6.59 for every dollar of annual earnings.
Moving Average
BlackRock Resources’s value is below its 50-day moving average of $8.68 and under its 200-day moving average of $8.99.
Volume
Today’s last reported volume for BlackRock Resources is 605835 which is 77.41% above its average volume of 341477.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of $1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing $1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 1% and 1%, respectively.
